title: Omalizumab. An option in vernal keratoconjunctivitis?
authors.forename: J
authors.initials: J
authors.lastname: Sánchez
authors.forename: R
authors.initials: R
authors.lastname: Cardona
mesh_terms: D000293:Adolescent; D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003233:Conjunctivitis, Allergic / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D016039:Corneal Transplantation; D016572:Cyclosporine / Q000627:therapeutic use; D018572:Disease-Free Survival; D004351:Drug Resistance; D005123:Eye / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D007165:Immunosuppression Therapy; D007640:Keratoconus / Q000473:pathology; D008297:Male; D000069444:Omalizumab; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D016572:Cyclosporine